Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25735749 | 0.88 | — | — | |
| SCHEMBL5730954 | 0.81 | LTA4H (0.31) | LTA4HCES2 | |
| SCHEMBL15489317 | 0.79 | CYP1A2 (0.45) | ALDH1A1MEN1KMT2ALTA4HCES2 | |
| SCHEMBL1667685 | 0.79 | CES2 (0.39) | TSHRMEN1KMT2ALTA4HCES2 | |
| SCHEMBL17992598 | 0.79 | CES2 (0.44) | MEN1KMT2ALTA4HCES2 | |
| SCHEMBL18751717 | 0.76 | CES2 (0.48) | TSHRMEN1KMT2ALTA4HCES2 | |
| SCHEMBL9973392 | 0.76 | CES2 (0.48) | TSHRMEN1KMT2ALTA4HCES2 | |
| SCHEMBL26203820 | 0.76 | CES2 (0.48) | TSHRMEN1KMT2ALTA4HCES2 | |
| SCHEMBL9973396 | 0.76 | CES2 (0.48) | TSHRMEN1KMT2ALTA4HCES2 | |
| SCHEMBL27056796 | 0.76 | CES2 (0.48) | TSHRMEN1KMT2ALTA4HCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358940-B2 | K-Ras modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200247762-A1 | K-RAS MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-06 | — | — | US | disclosed |
| EP-2899197-B1 | OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEOSIDE HAVING GUANIDINE BRIDGE | UNIV OSAKA (JP) | 2017-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247762-A1 | K-RAS MODULATORS | KRAS, HRAS, NRAS | TSHR 2770/4885ALDH1A1 3564/4885TDP1 3974/4885 |
| US-11358940-B2 | K-Ras modulators | KRAS, HRAS, NRAS | TSHR 4139/4885ALDH1A1 3111/4885TDP1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.